Celecoxib up regulates the expression of drug efflux transporter ABCG2 in breast cancer cell lines

Iranian Journal of Pharmaceutical Research

Volumn 13, Issue 4, 2014, Pages 1391-1399

  Kalalinia, Fatemeh ^a   Elahian, Fatemeh ^a,b   Mosaffa, Fatemeh ^a   Behravan, Javad ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

ABCG2; ATP binding cassette transporter; Celecoxib; MCF 7; Multidrug resistance

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CELECOXIB; CYCLOOXYGENASE 2; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INHIBITION; CANCER RESISTANCE; CELL CULTURE; CHEMOSENSITIZATION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION;

EID: 84907292744     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Trebino CE, Stock JL, Gibbons CP, Naiman BM, Wachtmann TS, Umland JP, Pandher K, Lapointe JM, Saha S, Roach ML, Carter D, Thomas NA, Durtschi BA, McNeish JD, Hambor JE, Jakobsson PJ, Carty TJ, Perez JR and Audoly LP. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc. Natl. Acad. Sci. USA (2002) 100: 9044-9049.
2. Razmi A, Zarghi A, Arfaee S, Naderi N and Faizi* M. Evaluation of Anti-nociceptive and Anti-inflammatory Activities of Novel Chalcone Derivatives. Iran. J. Pharm. Res. (2013) 12: 153-159.
3. Surowiak P, Materna V, Matkowski R, Szczuraszek K, Kornafel J, Wojnar A, Pudelko M, Dietel M, Denkert B, Zabel M and Lage H. Relationship between the expression of cyclooxygenase 2 and MDR1/P- glycoprotein in invasive breast cancers and their prognostic significance. Breast Cancer Res. (2005) 7: 862-870.
4. Hashitani S, Urade M, Nishimura N, Maeda T, Takaoka K, Noguchi K and Sakurai K. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. Int. J. Oncol. (2003) 23: 665-672.
5. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ and Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. (2000) 60: 1306-1311.
6. Gasparini G, Longo R, Sarmiento R and Morabito A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol. (2003) 4: 605-615.
7. Patel VA, Dunn MJ and Sorokin A. Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J. Biol. Chem. (2002) 277: 38915-38920.
8. Zatelli MC, Luchin A, Piccin D, Tagliati F, Bottoni A, Vignali C, Bondanelli M and degli Uberti EC. Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism. J. Clin. Endocrinol. Metab. (2005) 90: 5754-5760.
9. Mao Q and Unadkat JD. Role of the breast cancer resistance protein (ABCG2) in drug transport. Aaps. J. (2004) 7: 118-133.
10. Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, Mercer KE, Sarkadi B, Sorrentino BP and Schuetz JD. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J. Biol. Chem. (2004) 279: 24218-24225.
11. Sarkadi B, Ozvegy-Laczka C, Nemet K and Varadi A. ABCG2 - a transporter for all seasons. FEBS Lett. (2004) 567: 116-120.
12. Mosaffa F, Lage H, Afshari JT and Behravan J. Interleukin-1 beta and tumor necrosis factor-alpha increase ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX. Inflamm Res. (2009) 58: 669676.
13. Mosaffa F, Kalalinia F, Parhiz BH and Behravan J. Tumor Necrosis Factor Alpha Induces Stronger Cytotoxicity in ABCG2-Overexpressing Resistant Breast Cancer Cells Compared with Their Drug- Sensitive Parental Line. DNA Cell Biol. (2011).
14. Elahian F, Kalalinia F and Behravan J. Dexamethasone downregulates BCRP mRNA and protein expression in breast cancer cell lines. Oncol Res. (2009) 18: 9-15.
15. Kalalinia F, Elahian F and Behravan J. Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines. J. Cancer Res. Clin. Oncol. (2011) 137: 321-330.
16. Elahian F, Kalalinia F and Behravan J. Evaluation of indomethacin and dexamethasone effects on BCRP- mediated drug resistance in MCF-7 parental and resistant cell lines. Drug Chem. Toxicol. (2010) 33: 113-119.
17. Shen SC, Ko CH, Hsu KC and Chen YC. 3-OH flavone inhibition of epidermal growth factor-induced proliferaton through blocking prostaglandin E2 production. Int. J. Cancer. (2004) 108: 502-510.
18. Kalalinia F, Elahian F, Hassani M, Kasaeeian J and Behravan J. Phorbol Ester TPA Modulates Chemoresistance in the Drug Sensitive Breast Cancer Cell Line MCF-7 by Inducing Expression of Drug Efflux Transporter ABCG2. Asian Pac. J. Cancer Prev. (2012) 13: 2979-2984.
19. Puhlmann U, Ziemann C, Ruedell G, Vorwerk H, Schaefer D, Langebrake C, Schuermann P, Creutzig U and Reinhardt D. Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells. J. Pharmacol. Exp. Ther. (2005) 312: 346-354.
20. Ziemann C, Schafer D, Rudell G, Kahl GF and Hirsch- Ernst KI. The cyclooxygenase system participates in functional mdr1b overexpression in primary rat hepatocyte cultures. Hepatol. (2002) 35: 579-588.
21. Ratnasinghe D, Daschner PJ, Anver MR, Kasprzak BH, Taylor PR, Yeh GC and Tangrea JA. Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible? Anticancer Res. (2001) 21: 21412147.
22. Raspollini MR, Amunni G, Villanucci A, Boddi V and Taddei GL. Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170 (MDR1) expression is associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with low and high survival. Int. J. Gynecol. Cancer (2005) 15: 255260.
23. Saikawa Y, Sugiura T, Toriumi F, Kubota T, Suganuma K, Isshiki S, Otani Y, Kumai K and Kitajima M. Cyclooxygenase-2 gene induction causes CDDP resistance in colon cancer cell line, HCT-15. Anticancer Res. (2004) 24: 2723-2728.
24. Niederberger E, Tegeder I, Vetter G, Schmidtko A, Schmidt H, Euchenhofer C, Brautigam L, Grosch S and Geisslinger G. Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF- kappaB. Faseb. J. (2001) 15: 1622-1624.
25. Zrieki A, Farinotti R and Buyse M. Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line. Pharm. Res. (2008) 25: 1991-2001.
26. Kim SK, Lim SY, Wang KC, Kim YY, Chi JG, Choi YL, Shin HJ and Cho BK. Overexpression of cyclooxygenase-2 in childhood ependymomas: role of COX-2 inhibitor in growth and multi-drug resistance in-vitro. Oncol Rep. (2004) 12: 403-409.
27. Kang HK, Lee E, Pyo H and Lim SJ. Cyclooxygenase- independent down-regulation of multidrug resistance- associated protein-1 expression by celecoxib in human lung cancer cells. Mol. Cancer Ther. (2005) 4: 13581363.
28. Zatelli MC, Luchin A, Tagliati F, Leoni S, Piccin C, Bondanelli M, Rossi R and degli Uberti EC. Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression. Endocr. Relat. Cancer. (2007) 14: 1029-1038.
29. Huang L, Wang C, Zheng W, Liu R, Yang J and Tang C. Effects of celecoxib on the reversal of multidrug resistance in human gastric carcinoma by downregulation of the expression and activity of P-glycoprotein. Anticancer Drugs (2007) 18: 10751080.
30. Roy KR, Reddy GV, Maitreyi L, Agarwal S, Achari C, Vali S and Reddanna P. Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line. Cancer Chemother. Pharmacol. (2010) 65: 903-911.